Signal active
Investment Firm
Overview
Kreos Capital is Europe's largest and leading provider of growth debt to high-growth companies with revenues up to €150 million. Since 1998, as the pioneer growth debt provider across the UK, Western Europe, Scandinavia and Israel: Kreos has completed nearly 450 transactions and committed €1.8 billion in 14 different countries. Kreos has a proven track record of adding value to portfolio companies and helping them to grow with additional capital and flexibility throughout their business cycle whilst working closely with both the portfolio company management team and their equity sponsors.
The Kreos global team has extensive debt financing, management and equity investing experience, covering the pan-European market from its locations in London, Tel Aviv and Stockholm.
Kreos is a value added partner, able to offer additional capital and more flexibility with lower equity dilution. Kreos's international team has extensive entrepreneurial, debt financing and equity investing experience, covering all local European markets from its locations in London, Tel Aviv and Stockholm.
Highlights
1998
Financial Services
11-50
139
56
59
Late Stage Venture, Early Stage Venture, Seed
Venture Capital, Venture Debt
Location
Europe
Contact Information
Social
Profile Resume
Kreos Capital, established in 1998 and headquartered in Europe., specializes in Late Stage Venture, Early Stage Venture, Seed investments across Mobile, Telecommunications, Service Industry, Financial Services, Venture Capital, Finance, Analytics, Network Security, Software, Network Hardware. The organization boasts a portfolio of 139 investments, with an average round size of $30.6M and 59 successful exits. Their recent investments include Celtro, Rho Capital Partners, Cedar Fund, Momentum Venture Management, ECI Telecom. The highest investment round they participated in was $275.1B. Among their most notable exits are Celtro and Rho Capital Partners. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Investment portfolio
139
1
56
59
Investments
139
Annouced Date | Organization Name | Industry | Money Raised |
---|---|---|---|
Feb 01, 2023 | Sdui | Software | 19.8M |
Jul 24, 2023 | Crescendo Biologics | Biotechnology | 32.0M |
Aug 21, 2023 | Abivax | Biotechnology | 163.5M |
Apr 10, 2024 | BiolineRx | Biotechnology | 20.0M |
Exits
59
Funding Timeline
139
0
4
Funding Rounds
139
Kreos Capital has raised 139 rounds. Their latest funding was raised on Apr 10, 2024 from a Post-IPO Debt - BiolineRx round.
Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
---|---|---|---|---|
Feb 01, 2023 | Series A - Sdui | - | 19.8M | - |
Jul 24, 2023 | Venture Round - Crescendo Biologics | - | 32.0M | - |
Aug 21, 2023 | Post-IPO Debt - Abivax | - | 163.5M | - |
Apr 10, 2024 | Post-IPO Debt - BiolineRx | - | 20.0M | - |
Investors
0
There is no funding round available on this profile
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
Annouced Date | Fund Name | Money Raised |
---|---|---|
May 10, 2013 | OTPPLESS | 1.0M |
May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
There is no recent news or activity for this profile.